• News
  • SAN DIEGO
  • BioTech

Orexigen falls on three-month extension of weight-loss pill

Orexigen Therapeutics Inc. fell the most in three years after regulators pushed back a decision on whether to approve the company’s obesity drug NB32.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
5.34
  0.05  
+ 0.95%
2,798,380,000
7.84
4.59

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Subscribe Today!